Chiasma Competitors

Chiasma (NASDAQ:CHMA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Chiasma and Calliditas Therapeutics AB (publ), as reported by MarketBeat.

Chiasma currently has a consensus price target of $11.6667, suggesting a potential upside of 300.92%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, suggesting a potential upside of 51.39%. Given Chiasma's higher probable upside, research analysts plainly believe Chiasma is more favorable than Calliditas Therapeutics AB (publ).

Institutional & Insider Ownership

71.3% of Chiasma shares are owned by institutional investors. Comparatively, 11.9% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 5.5% of Chiasma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Chiasma and Calliditas Therapeutics AB (publ)'s gross revenue, earnings per share (EPS) and valuation.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Chiasma. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Chiasma and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Summary

Calliditas Therapeutics AB (publ) beats Chiasma on 6 of the 10 factors compared between the two stocks.

Chiasma (NASDAQ:CHMA) and Kadmon (NASDAQ:KDMN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Risk & Volatility

Chiasma has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Kadmon has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Earnings and Valuation

This table compares Chiasma and Kadmon's gross revenue, earnings per share (EPS) and valuation.

Chiasma has higher earnings, but lower revenue than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Chiasma and Kadmon, as reported by MarketBeat.com.

Chiasma currently has a consensus target price of $11.6667, suggesting a potential upside of 300.92%. Kadmon has a consensus target price of $12.75, suggesting a potential upside of 226.92%. Given Chiasma's higher possible upside, analysts plainly believe Chiasma is more favorable than Kadmon.

Profitability

This table compares Chiasma and Kadmon's net margins, return on equity and return on assets.

Insider and Institutional Ownership

71.3% of Chiasma shares are owned by institutional investors. Comparatively, 94.8% of Kadmon shares are owned by institutional investors. 5.5% of Chiasma shares are owned by insiders. Comparatively, 3.0% of Kadmon shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Chiasma (NASDAQ:CHMA) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Risk and Volatility

Chiasma has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.

Institutional and Insider Ownership

71.3% of Chiasma shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 5.5% of Chiasma shares are held by insiders. Comparatively, 6.6% of Clovis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Chiasma and Clovis Oncology's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for Chiasma and Clovis Oncology, as provided by MarketBeat.com.

Chiasma currently has a consensus target price of $11.6667, suggesting a potential upside of 300.92%. Clovis Oncology has a consensus target price of $9.50, suggesting a potential upside of 52.00%. Given Chiasma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Chiasma is more favorable than Clovis Oncology.

Valuation and Earnings

This table compares Chiasma and Clovis Oncology's top-line revenue, earnings per share (EPS) and valuation.

Chiasma has higher earnings, but lower revenue than Clovis Oncology. Chiasma is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Chiasma beats Clovis Oncology on 7 of the 12 factors compared between the two stocks.

Gossamer Bio (NASDAQ:GOSS) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Insider and Institutional Ownership

72.0% of Gossamer Bio shares are owned by institutional investors. Comparatively, 71.3% of Chiasma shares are owned by institutional investors. 23.3% of Gossamer Bio shares are owned by insiders. Comparatively, 5.5% of Chiasma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Gossamer Bio and Chiasma's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Gossamer Bio and Chiasma's revenue, earnings per share (EPS) and valuation.

Chiasma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gossamer Bio has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Gossamer Bio and Chiasma, as provided by MarketBeat.

Gossamer Bio currently has a consensus price target of $23.00, indicating a potential upside of 169.64%. Chiasma has a consensus price target of $11.6667, indicating a potential upside of 300.92%. Given Chiasma's higher probable upside, analysts clearly believe Chiasma is more favorable than Gossamer Bio.

Rigel Pharmaceuticals (NASDAQ:RIGL) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Earnings and Valuation

This table compares Rigel Pharmaceuticals and Chiasma's top-line revenue, earnings per share and valuation.

Chiasma has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 71.3% of Chiasma shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Chiasma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Rigel Pharmaceuticals and Chiasma, as provided by MarketBeat.

Rigel Pharmaceuticals currently has a consensus target price of $8.3333, indicating a potential upside of 123.41%. Chiasma has a consensus target price of $11.6667, indicating a potential upside of 300.92%. Given Chiasma's stronger consensus rating and higher possible upside, analysts plainly believe Chiasma is more favorable than Rigel Pharmaceuticals.

Profitability

This table compares Rigel Pharmaceuticals and Chiasma's net margins, return on equity and return on assets.

Risk and Volatility

Rigel Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Summary

Chiasma beats Rigel Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Relmada Therapeutics (NASDAQ:RLMD) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and target prices for Relmada Therapeutics and Chiasma, as reported by MarketBeat.com.

Relmada Therapeutics currently has a consensus price target of $63.3333, suggesting a potential upside of 72.24%. Chiasma has a consensus price target of $11.6667, suggesting a potential upside of 300.92%. Given Chiasma's stronger consensus rating and higher probable upside, analysts clearly believe Chiasma is more favorable than Relmada Therapeutics.

Risk & Volatility

Relmada Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Institutional & Insider Ownership

64.3% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 71.3% of Chiasma shares are owned by institutional investors. 9.3% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Chiasma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Relmada Therapeutics and Chiasma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Relmada Therapeutics and Chiasma's revenue, earnings per share (EPS) and valuation.

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.

Summary

Chiasma beats Relmada Therapeutics on 6 of the 9 factors compared between the two stocks.